Silence Therapeutics (Nasdaq:SLN), is a London-based pharmaceutical company formed in 1994. Since its origin, the company has been a pioneer in the design and development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London). Silence Therapeutics develops medicines by utilising the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet needs. Silence's mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that target and silence disease-associated genes in the liver. Silence Therapeutic's product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases. More information...
According to PR-model, silence-therapeutics.com is ranked 1,861,974th in multilingual Wikipedia, in particular this website is ranked 1,031,194th in English Wikipedia.
The website is placed before glama.it and after bromeliad.com in the BestRef global ranking of the most important sources of Wikipedia.
